Cadrenal Therapeutics stock soars due to Phase 2 clinical trial results

LootboxPhobia · 2026-02-25T04:01:44+00:00

Cadrenal Therapeutics Inc's stock price rose 11% due to the results of Phase 2 clinical trials for CAD-1005 in treating heparin-induced thrombocytopenia. Although the primary endpoint was not met, the incidence of thrombotic events in the CAD-1005 group was lower than in the placebo group. The drug has received FDA orphan drug designation, targeting the immune mechanism of HIT.

LootboxPhobia

2026-02-25 04:01:44

Abstract generation in progress

Investing.com – Cadrenal Therapeutics Inc (NASDAQ:CVKD) stock surged 11% on Tuesday after the company announced encouraging results from a Phase 2 clinical trial of CAD-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

The trial showed that although both groups of patients received standard anticoagulation therapy, the CAD-1005 treatment group had a lower incidence of thrombotic events than the placebo group. The incidence of thrombotic events in the placebo group was over 75%, while in the CAD-1005 group it was 50%, although the study did not meet the sample size requirements for statistical significance.

This randomized, double-blind, placebo-controlled trial evaluated the efficacy of CAD-1005 (a selective 12-lipoxygenase inhibitor) in 24 suspected HIT patients. The primary endpoint, platelet count recovery rate, was not met, with similar recovery rates between the two treatment groups. However, the company noted that thrombotic events continued to occur in both groups after platelet counts recovered.

Cadrenal has scheduled a meeting with the FDA in March 2026 to discuss the Phase 3 registration pathway. The company acquired the CAD-1005 program from Veralox Therapeutics, with the transfer of ownership completed in December 2025.

HIT is a potentially life-threatening immune-mediated complication affecting patients receiving heparin, which is the most widely used anticoagulant in hospitals. Over 12 million patients in the U.S. receive heparin annually. Some studies report a mortality rate for HIT exceeding 20%.

CAD-1005 has received orphan drug designation and fast track designation from the FDA, as well as orphan drug status from the European Medicines Agency. The drug aims to target the underlying immune mechanisms driving HIT, which is different from existing therapies that only address thrombotic complications.

The trial originally planned to enroll 60 patients but was halted in December 2025 after the project transfer.

This article was translated with artificial intelligence assistance. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.